Introduction: Platelets are routinely isolated from whole blood and stored in plasma for 5 days. The platelets undergo various storage changes starting from collection, processing to storage and the underlying conditions within the patients which may affect the therapeutic benefit to the recipient. Study aimed to assess the quality of platelets in platelet rich plasma and platelet concentrate and to evaluate the effects of storage on platelets in platelet rich plasma and platelet concentrate. Material and methods:The study was carried out in the after obtaining approval from the Institutional Ethical Committee. The study period was six months. The samples were collected from platelet rich plasma and platelet concentrate bags under sterile conditions. Their quality was assessed using the parameters such as swirling, volume of the platelet concentrate, platelet count, WBC count and pH on day 0, day 3 and day 5 of storage.Results: A total of 64 samples were evaluated and of these 95% have fullfilled all 5 parameters of quality control with a score 5 and 5% had score 4. Thus in our study majority of the prepared units were of the desired quality. All the parameters were assessed and the results obtained on both the units were well above the values of recommended norms. Conclusion:The quality of platelet concentrates were maintained well within the usual 5 days thus an extension of platelet storage time is recommended.
BACKGROUND Haemolytic Disease of Fetus and Newborn (HDFN) is characterised by lysis of red blood cells resulting in anaemia and its hypoxic effects thereafter. Following anaemia, the production of fetal red blood cells is drastically increased. This is followed by extramedullary haematopoiesis in a widespread manner and erythroblastosis characterized by nucleated red cells in the circulation. Since this is an illness affecting many a newborn, assessing the patterns of anaemia in both ABO and Rh-D HDFN may help in effective planning and implementation of better management protocols. METHODS This is a cross sectional study with comparative analysis. The study was performed among 154 neonates who were diagnosed to have HDFN. Setting for this study was Department of Transfusion Medicine and Pediatrics of Government Medical College, Trivandrum. During the time of delivery, 5 mL umbilical cord blood was collected. That sample was used for analyzing haemoglobin levels of the neonate. Duration of treatment of the neonate was noted down during follow up. Statistical analysis was done using SPSS software version 16. RESULTS The mean cord blood haemoglobin value in ABO haemolytic disease was 17.1 ± 2.7 g %. The mean cord blood haemoglobin value in Rh-D haemolytic disease was 14.5 ± 1.9 g %. In infants with ABO haemolytic disease, 53 (48.2 %) had undergone no treatment in ICU. Remaining 51.8 % had undergone 3 - 10 days of treatment in neonatal ICU. Infants with Rh-D HDFN 20 (45.5 %), had undergone no treatment in ICU. Remaining 54.5 % has got 3 - 9 days of treatment in neonatal ICU. Mean treatment duration in infants with ABO haemolytic disease was 3.1 ± 3.3 days. Mean treatment duration in infants with Rh-D haemolytic disease was 2.9 ± 2.9 days. A comparison of mean values of cord blood haemoglobin in neonates with both categories of haemolytic disease was performed. The p value was 0.00 and it was significant. Mean values of duration of treatment of neonates with ABO and Rh-D haemolytic anaemias were compared statistically. No significant difference was observed. CONCLUSIONS Mean haemoglobin levels in Rh-D HDFN showed a significant decrease as compared to ABO-HDFN. Duration of treatment in ABO HDFN and Rh-D HDFN presented no significant difference. KEYWORDS Haemolytic Disease of Fetus and Newborn, Umbilical Cord Haemoglobin, Anaemia, ICU Stay, ABO HDFN, Rh-D HDFN
BACKGROUNDThe potency of anti-A and anti-B was determined by racial and environmental factors. With respect to ethnic groups, the prevalence and intensity of maternal-newborn ABO incompatibility varied in different populations. The aim of this study is to describe the immunological profile of ABO HDFN. Settings and Design-This was a descriptive study conducted in neonates with ABO HDFN. Research was conducted in Depts. of Transfusion Medicine and Neonatology division of Paediatrics in Govt. Medical College, Trivandrum. MATERIALS AND METHODSThose neonates who fulfilled the inclusion criteria were enrolled in this study. Demographic details, maternal details, bilirubin and haemoglobin levels were recorded. Investigations such as maternal blood grouping and antibody titration were done. In infant's blood sample direct antiglobulin test, blood grouping and elution was performed.Statistical Analysis-All statistical data were analysed using SPSS software version 16. RESULTSAmong mothers of infants with ABO HDFN 25 (22.7%) had a titre of 128, 34 (30.9%) had 256, 35 (31.8%) had 512 and 16 (14.6%) had 1024. Among 110 infants 34 (30.9%) were DAT positive, while the rest 76 (69.1%) were DAT negative. While DAT positive was graded 13 (11.8%) fell in grade 1, 16 (14.6%) in grade 2, 3 (2.7%) in grade 3 and 2 (1.8%) in grade 4 categories. Eluate from 59 (53.6%) of infants with ABO HDFN gave a positive result, while the rest 51 (46.4%) gave a negative result. Out of that 59 (53.6%) elution positive infants, 34 (30.9%) had a positive DAT and 25 (22.7%) had a negative DAT; 51 (46.4%) of infants were negative for both elution and DAT. CONCLUSIONMothers of infants with ABO HDFN had an antibody titre of 128 -1024. Almost one-third of infants were DAT positive and majority fell in grade 1 or 2. Eluate from half of infants gave a positive result.
Introduction: Breast cancer is the commonest cancer in urban Indian females, and the second commonest in the rural Indian women. The estimated number of breast cancer cases in India during 2012 was 145,000 cases with an incidence rate of 25.8 per 100,000 women. In Kerala, Breast cancer has an annual incidence of 14.9/100,000 population. This study was carried out with an objective to identify the proportion of thrombocytopenia and the requirement of platelet transfusions in these patients. Material and methods: This was a hospital based prospective study, done in the Department of Transfusion medicine for a period of one and a half years from January 2016 to June 2017. As per the inclusion criteria 125 consecutive cases who underwent chemotherapy for Carcinoma Breast at Department of Radiotherapy, Govt. Medical College, Thiruvananthapuram were included for the study. The requirement of platelet transfusions were assessed in these patients. Data was analysed with SPSS software (version 21). Results: Among the 125 patients, thrombocytopenia was noticed in 5.4% study population in prechemotherapy phase, majority having only grade I thrombocytopenia. In Post chemo phase thrombocytopenia was observed in 11.2% of the study group, grade I thrombocytopenia in 8.8% and grade II thrombocytopenia 2.4% of patients. Platelet transfusion was required in 5.4% of the patients during chemotherapy. Conclusion: Due to the high prevalence of chemotherapyinduced hematological complications, even mild degrees of thrombocytopenia should be detected and evaluated before commencing chemotherapy. Platelet transfusion should be reserved for patients who were really required. This study gives an insight regarding the proportion of thrombocytopenia in patients with carcinoma breast undergoing chemotherapy and their platelet transfusion requirements, which will help in taking care of these patients and inventory management of the blood banks.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.